4. Hospital re‐admissions and return healthcare visits (in‐ and outpatients).
| Study | Population | Duration of follow‐up | Glucocorticoid‐including group | Placebo or comparator group | Notes |
| GLUCOCORTICOID AND EPINEPHRINE versus PLACEBO: HOSPITAL RE‐ADMISSIONS | |||||
| Roosevelt 1996 | Inpatients | Days 1 to 14 | 0 | 0 | (No events in either group) |
| Klassen 1997 | Inpatients | Days 1 to 7 | 4/35 (11%) | 1/32 (3%) | P = 0.36 |
| Teeratakulpisarn 2007 | Inpatients | Days 1 to 30 | 3/89 (3%) | 7/85 (8%) | |
| GLUCOCORTICOID versus PLACEBO: RETURN HEALTHCARE VISITS* | |||||
| Plint 2009 (epinephrine ‐ E; dexamethasone ‐ D; placebo ‐ P) |
Outpatients | Days 1 to 22 | D + E 95/199 (48%) |
P + E 93/198 (47%) |
Return to the health care provider for bronchiolitis symptoms Difference between dexamethasone + placebo versus placebo + placebo, was significant in the unadjusted analysis (P = 0.04) |
| D + P 106/199 (53%) |
P + P 86/201 (43%) |
||||
| Schuh 2002 | Outpatients | Days 7 to 28 | 9/35 (26%) | 14/32 (44%) | Medical visits for continuing symptoms; P = 0.069 |
| Klassen 1997 | Inpatients | Days 1 to 7 | 29/35 (83%) | 24/32 (75%) | P = 0.77 |
| Roosevelt 1996 | Inpatients | Days 1 to 14 | 16/65 (25%) | 5/53 (9%) | P = 0.01; reported on visits made by the physician; 69% were for non‐respiratory difficulties |
| Teeratakulpisarn 2007 | Inpatients | Days 1 to 30 | 17/89 (19%) | 26/85 (31%) | Visit to emergency room or a private clinic because of respiratory symptoms |
| GLUCOCORTICOID versus EPINEPHRINE: RETURN HEALTHCARE VISITS | |||||
| Plint 2009 (dexamethasone + placebo versus epinephrine + placebo) |
Outpatients | Days 1 to 22 | 106/199 (53%) | 93/198 (47%) | ‐ |
| GLUCOCORTICOID AND EPINEPHRINE versus PLACEBO: RETURN HEALTHCARE VISITS | |||||
| Plint 2009 (dexamethasone + epinephrine versus placebo + placebo) |
Outpatients | Days 1 to 22 | 95/198 (48%) | 86/201 (43%) | ‐ |
*Berger 1998: no difference between groups, but did not report quantitative data. Data presented as n/N (%)